| 000 | 01781 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517132421.0 | ||
| 264 | 0 | _c20170313 | |
| 008 | 201703s 0 0 eng d | ||
| 022 | _a1096-0295 | ||
| 024 | 7 |
_a10.1016/j.yrtph.2016.12.011 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHarvey, James | |
| 245 | 0 | 0 |
_aManagement of organic impurities in small molecule medicinal products: Deriving safe limits for use in early development. _h[electronic resource] |
| 260 |
_bRegulatory toxicology and pharmacology : RTP _cMar 2017 |
||
| 300 |
_a116-123 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aClinical Trials as Topic _xlegislation & jurisprudence |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Contamination |
| 650 | 0 | 4 |
_aDrug Discovery _xlegislation & jurisprudence |
| 650 | 0 | 4 | _aDrug and Narcotic Control |
| 650 | 0 | 4 | _aGovernment Regulation |
| 650 | 0 | 4 | _aHealth Policy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aNo-Observed-Adverse-Effect Level |
| 650 | 0 | 4 |
_aOrganic Chemicals _xadverse effects |
| 650 | 0 | 4 |
_aPatient Safety _xlegislation & jurisprudence |
| 650 | 0 | 4 |
_aPharmaceutical Preparations _xanalysis |
| 650 | 0 | 4 | _aPolicy Making |
| 650 | 0 | 4 | _aQuality Control |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aThreshold Limit Values |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 |
_aToxicity Tests _xmethods |
| 700 | 1 | _aFleetwood, Andrew | |
| 700 | 1 | _aOgilvie, Ron | |
| 700 | 1 | _aTeasdale, Andrew | |
| 700 | 1 | _aWilcox, Phil | |
| 700 | 1 | _aSpanhaak, Steven | |
| 773 | 0 |
_tRegulatory toxicology and pharmacology : RTP _gvol. 84 _gp. 116-123 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.yrtph.2016.12.011 _zAvailable from publisher's website |
| 999 |
_c26743302 _d26743302 |
||